Cargando…
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
AIM: Post‐hoc analysis of the efficacy and safety of ertugliflozin in East/Southeast (E/SE) Asian patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: Efficacy evaluations used data from randomized, double‐blind, phase 3 studies: a pool of two 26‐week placebo‐controlled studies and...
Autores principales: | Liu, Jie, Patel, Shrita, Cater, Nilo B., Wu, Larry, Huyck, Susan, Terra, Steven G., Hickman, Anne, Darekar, Amanda, Pong, Annpey, Gantz, Ira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078752/ https://www.ncbi.nlm.nih.gov/pubmed/31797522 http://dx.doi.org/10.1111/dom.13931 |
Ejemplares similares
-
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
por: Patel, Shrita, et al.
Publicado: (2020) -
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
por: Liu, Jie, et al.
Publicado: (2019) -
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
por: Cherney, David Z. I., et al.
Publicado: (2020) -
Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
por: Heymsfield, Steven B., et al.
Publicado: (2020) -
Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
por: Gallo, Silvina, et al.
Publicado: (2019)